UCal further strengthens CRISPR position in Europe, but Cas9 licensing situation remains tricky
EPO Opposition Division upholds another key Doudna patent, but several gene-editing appeals are still in play
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.